VEGFA and neoplasm: The monoclonal VEGF antibody A4.6.1 significantly decreases VD, tumour growth, and IFP, in several tumour models including colorectal cancer (Kim et al, 1993; Borgstrom et al, 1998; Lee et al, 2000; Rowe et al, 2000).